Photodynamic therapy is a photochemical technique for the local destruction of tumours, entailing the interaction of light with an administered photosensitiser to produce a cytotoxic effect. We investigated the tissue distribution of the photosensitiser aluminium sulphonated phthalocyanine (A1SPc) in dimethylhydrazine induced colonic tumours and adjacent normal colon in rats.
H Barr, P Chatlani, C J Tralau, A J MacRobert, P B Boulos, S G Bown Abstract Photodynamic therapy is a photochemical technique for the local destruction of tumours, entailing the interaction of light with an administered photosensitiser to produce a cytotoxic effect. We investigated the tissue distribution of the photosensitiser aluminium sulphonated phthalocyanine (A1SPc) in dimethylhydrazine induced colonic tumours and adjacent normal colon in rats. Forty eight hours after intravenous injection, most tumours contained twice as much AlSPc as normal colon. Tumour size and position in the colon did not affect AISPc concentration. Microscopic fluorescence localisation of AISPc showed significant photosensitiser accumulation in tumour stroma, whereas tumour and normal mucosa contained similar amounts. Thus, some normal tissue damage, where malignant cells invade normal areas, would inevitably accompany eradication of tumours. Tumour destruction and healing of colon after tumour eradication were examined histologically. There was sharp demarcation between necrotic areas (tumour or normal) and adjacent tissue and, whether the treated area was tumour or normal, healing occurred by regeneration of normal tissue. Some incompletely eradicated large tumours showed evidence of delayed bleeding. The possibility of selective uptake or preferential retention of the photosensitiser in tumours formed the initial basis for investigation of photodynamic therapy, but it is now clear that this is seldom the most important factor for tumour eradication. Offar greater importance is the nature of the biological effect of photodynamic therapy as necrosis of small tumours involving the full thickness of the bowel wall can be achieved with safe healing by regeneration of normal colon. The maximum depth of necrosis produced was only a few millimetres, so this technique is unlikely to be of value as the primary treatment for large colonic tumours but may prove of value for eradicating small lesions or as adjunctive therapy for eradication of small nests oftumour remaining or recurring in the tumour bed after conventional surgery.
Photodynamic therapy entails the administration of a photosensitiser with subsequent activation with light to produce a local cytotoxic effect. It initially attracted interest because parenterally administered photosensitisers, such as haemoporphyrin, showed increased fluorescence in malignant tumours in relation to surrounding normal tissue.' Thus it seemed that an advantageous therapeutic ratio existed between normal and malignant tissue, although it is now clear that this tumour selectivity is not as dramatic as was first thought.
Cancer Figure 1 shows the apparatus with an excitation light source using a 1 mW helium neon laser (632-8 nm).
Tumour bearing animals were injected with AlSPc (5 mg/kg) and killed from 1-168 hours later. Tumour and adjacent colon samples were taken and dropped into a beaker of 20 ml of isopentane (2 methylbutane),which had been cooled in a Dewar flask of liquid nitrogen. The snap frozen tissue samples were stored in liquid nitrogen until sectioned. The tissue blocks were mounted on OCT medium (tissue tek II embedding compound, BDH) and 6 Rm sections cut These tumours are prone to produce rectal bleeding and an attempt was made to clarify the risk of delayed haemorrhage that has been asssociated with photodynamic therapy.'3 All animals were examined after phototherapy for evidence of rectal bleeding and at postmortem the entire colon was examined for blood. Evidence of bleeding was also sought in some animals with large tumours that were deliberately treated with a light dose that would only partially eradicate the tumour to see if this changed the risk of bleeding. The purpose of this part of the work was to eradicate individual tumours and observe the nature of the subsequent healing. Photodynamic therapy was performed 48 hours after photosensitisation (the time when the tumour:normal colon ratio was at its maximum, 2:1). The animals were anaesthetised and a midline laparotomy performed. The site of the tumour was identified by palpation and a longitudinal colotomy performed opposite the base ofthe tumour. All faeces were washed from the tumour and a light dose chosen (with reference to previous quantitative studies7) that Figure 2 shows the ratio of AlSPc uptake between dimethylhydrazine tumours and adjacent normal colon as measured by chemical extraction. Each point is the ratio between the tumour and the colon in which it arose in the same animal. These data confirm our earlier study,6 although the maximum mean ratio 48 hours after photosensitisation is slightly smaller at just over 2:1 compared with 2-8:. The striking feature is the range of values found with some tumours at 48 hours having the same concentration of AlSPc as the adjacent normal colon. Figure 3 shows the ratio correlated with the size of tumour and Figure 4 shows the ratio compared with the position in the colon. Neither of these two factors influences the therapeutic ratio.
Results

MICROSCOPIC DISTRIBUTION OF AlSPc
The table shows the quantitative results from fluorescence microscopy of tumour and adjacent normal colon. The most important finding is that the only significant difference between the highest fluorescence emission from any part of the tumour and from any part of the normal colon at the same time after sensitisation occurred 48 hours after photosensitisation and was between the normal mucosa and the tumour stroma. The malignant mucosa never contained significantly more AlSPc than the adjacent normal mucosa. It (mm) is also clear that the uptake of the photosensitiser is different in various parts of the tissue with the peak concentration occurring at different times. This phenomenon is being examined in more detail and is related to tissue vascularity and components that bind the photosensitiser.
PHOTODYNAMIC THERAPY OF DIMETHYLHYDRAZINE TUMOURS
The histological progression ofdamage in normal colon after photodynamic therapy has been described previously. 5 The nature of damage in tumours seen in this study was similar with an initial vascular dilatation, haemorrhage, and subsequent shutdown. Figure 5 shows a tumour 48 hours after photodynamic therapy. The necrotic tumour is separating from its pedicle and adjacent normal colon. The striking feature of this section is the sharp demarcation between necrotic and viable tissue, confirming the important fact that a threshold photodynamic therapy dose is required for necrosis in these tumours as in the normal colon.5 By 72 hours the tumour was necrotic and had separated and all that remained was a defect in a normal area of colon wall or a viable area of tumour. Figure 6 shows an area ofcolon that previously contained a tumour. The tumour was treated with a photodynamic dose (photosensitiser/light combination) appropriate for complete eradication. At postmortem, there was no macroscopic abnormality but this area was found on serial section, showing regenerating mucosa encroaching on a small ulcerated area which was presumably the site of tumour attachment to the colon. micrograph there is florid regeneration ofmucosa with thickening of the submucosa and serosa. There is no muscle present under the small ulcer but the histological distribution of the muscle in relation to the tumour was not known before treatment. Thus no precise comment can be made.
There was no evidence of haemorrhage when tumour eradication was complete. In this series only three tumours showed evidence of haemorrhage. In none did the bleeding affect the clinical condition of the animal, and in all it was only discovered at postmortem. The feature of these tumours was that they had been substantially undertreated. They were relatively large (approximately 2 photosensitiser was not a process specific to the photosensitiser but more a non-specific property of tumour tissue.6 The more detailed study of the uptake of AlSPc in dimethylhydrazine tumours in this paper shows that if we compare the tumour directly with the colon in which it arose and calculate the ratio for each tumour the best therapeutic ratio of 2:1 occurs 48 hours after photosensitisation. It is clear, however, from Figure 2 that there is a wide variation in tumours. It is therefore important to identify any factors in tumours that may account for this variation.
Bellnier et al' showed that the uptake of dihaemoporphyrin ether/ester in subcutaneous tumours varied inversely with their weight. These tumours are fast growing and rapidly outgrow their blood supply, therefore it may be that the larger tumours retained less dihaemoporphyrin ether/ester in necrotic areas. The dimethylhydrazine tumour is different in that we rarely see spontaneous necrosis, and necrotic areas tend to slough and be removed. We compared the therapeutic ratio with the mean diameter and could not show any correlation, although few large tumours were available for examination as tumours were not allowed to develop further once the animals became symptomatic. The localisation of AlSPc by fluorescence microscopy showed that only the stroma associated with the tumour contained the photosensitiser in significantly greater quantities than the adjacent normal tissue, even at the time of the peak therapeutic ratio, 48 hours after injection. Normal colonic mucosa and tumour mucosa contained similar amounts of AlSPc. These findings agree with those of Bugelski et al14 who investigated haemoporphyrin derivative distribution using autoradiography in implanted tumours. Our study establishes that AISPc localises in a similar manner in an autochthonous tumour arising in its host tissue. Yet it was also shown that implanted polyvinyl sponges acting as model tumours localised porphyrin photosensitiser.'5 These results suggest that the retention of the photosensitiser is a non-specific effect and have important implications for the investigation of photodynamic therapy.
To eradicate a tumour all malignant cells must be destroyed, in particular those in the area where the tumour is invading normal tissue. It is now apparent that there is no beneficial therapeutic ratio between normal and malignant cells in this region, so to eradicate a tumour it will be necessary to use treatment parameters that kill at least some normal tissue.
It is now clear that photodynamic therapy of implanted tumours with both porphyrin and phthalocyanine photosensitisers produces profound effects on the tumour microvasculature. 16 Recent studies have shown that the overall tumour response is governed by vascular destruction and leads to increasingly nonselective tissue destruction as the photodynamic therapy dose increases. 7 In particular, in order to eradicate a tumour using porphyrins as photosensitisers, normal tissue9 or normal vasculature' has to be destroyed. It is clear that AlSPc uptake and microscopic distribution is very similar to that of porphyrins, and photosensitisers produce tissue damage in similar ways, so it can be expected that normal tissue would have to be destroyed to eradicate a tumour using the phthalocyanines as well. One aim of this study was to establish how the colon would heal after total destruction of the tumour. Healing occurred safely with regeneration of the colonic mucosa, so some degree of normal tissue damage is acceptable. Our previous studies showed that full thickness photodynamic therapy necrosis of normal rat colon healed without loss of mechanical strength as the submucosal collagen was undamaged and presumably acted as a template for healing by regeneration.'8 For a tumour that involves the full thickness of the bowel wall the normal collagen of the submucosa will be destroyed, so the studies on normal bowel cannot be directly extrapolated to say that necrosis of these tumours will heal safely. The present experiments have, however, shown that even tumours reaching through to the serosa can be destroyed with safe healing. Histological sections of untreated full thickness tumours show abundant stromal collagen which would explain our experimental results. An example of this is shown in Figure 7 . We have also looked at a small series of human colon cancers of the full thickness of the bowel wall after surgical removal (unpublished data) and shown that the stromal reaction includes production of large amounts of collagen (Fig 8) , so it may be possible to use photodynamic therapy to treat small human colon cancers penetrating through to the serosa without risk of perforation.
In one small study of the treatment of skin nodules with photodynamic therapy a striking feature was the nature ofhealing. After treatment an area of skin necrosis occurred with eschar formation, but it caused minimal pain and healed without scarring.'9 The nature of photodynamic therapy damage is different from thermal injury" and radiation necrosis, which often fails to heal. 9 These simple observations show important biological advantages for photodynamic therapy and provide a rational basis to proceed to clinical trials.
Reports ofmajor haemorrhage occurring when necrosed tumour separated a few days after photodynamic therapy to advanced bronchial carcinomas'3 are of considerable concern, although it is remarkable how little has been done to study this potentially fatal complication. Unfortunately, it is difficult to explore this problem experimentally. We were hoping to clarify this in the present study. At postmortem three of the rat colon cancers had adherent blood clot after separation of the necrotic tumour after photodynamic therapy. It is striking that bleeding was never evident after photodynamic therapy to the normal colon' nor was it evident when the tumour was completely eradicated. No definite conclusion can be drawn from such a small number of lesions, but considering these results with our own initial clinical data on the treatment ofcolorectal cancers20 in which haemodynamically significant haemorrhage occurred in one of 10 patients treated, it seems that bleeding is more prone to occur in large fleshy tumours which are only partly necrosed. The necrosed area seems to slough, leaving a raw tumour surface exposed that is likely to bleed.
In conclusion, the uptake and microscopic localisation of AlSPc follow a similar pattern to that of other photosensitisers and provide little hope of truly selective tumour eradication. Photodynamic therapy with AlSPc, however, can be used to eradicate tumours in the rat colon by producing necrosis in the tumour and in the adjacent normal colon that heals safely by regeneration of normal tissues. The necrosis that can be produced in these tumours only extends a few millimetres from the light source7 and if large tumours are only partially eradicated there is a small risk of delayed haemorrhage, so photodynamic therapy is not likely to find a role as a primary treatment for tumours more than a few millimetres in depth. The results described here suggest that it may be useful as an adjunctive therapy. If the main bulk of tumour is removed by another technique such as surgery, photodynamic therapy may be capable of eradicating small foci of malignant cells in the tumour bed either at the time of the original procedure or in the event of subsequent local recurrence. As long as it is known that any necrosed normal tissues in the area will heal safely by regeneration after photodynamic therapy necrosis, which is the case for normal colon, it is safe to treat the entire tumour bed to give the maximum chance of eradicating all remaining nests ofmalignant cells.
In the early days of photodynamic therapy many unrealistic claims were made about its potential for selective destruction of malignant tumours. Now that its effects on normal and tumour tissue are better understood a more realistic picture is emerging. It is not suitable for the primary management of large tumours, but may have a useful clinical role in eradicating small tumours or as an adjunct to conventional management of larger lesions.
